米非司酮对子宫肌瘤患者血清hs-CRP的影响  

Influence on Mifepristone in hysteromyoma patients' hs-CRP

作　　者：周伟[1] 辛华 杨绿舜[1] 林欢[1] 

机构地区：[1]广东省深圳市宝安区西乡人民医院,广东深圳518102 [2]广东省深圳市宝安区妇幼保健医院,广东深圳518101

出　　处：《中国医药导报》2010年第16期89-90,共2页China Medical Herald

摘　　要：目的:观察子宫肌瘤患者服用米非司酮治疗后,血清高敏C-反应蛋白(hs-CRP)浓度的改变,探讨米非司酮对子宫肌瘤患者的疗效。方法:应用散射比浊法测定100例子宫肌瘤患者经米非司酮治疗后的hs-CRP浓度,并与治疗前进行比较。结果:子宫肌瘤患者hs-CRP浓度水平总体高于正常人,米非司酮治疗子宫肌瘤患者前后的hs-CRP浓度比较,差异有统计学意义(P<0.01)。结论:子宫肌瘤患者经米非司酮治疗后的hs-CRP浓度明显减低,hs-CRP可作为米非司酮治疗子宫肌瘤的有效指标之一,米非司酮是一种有效、安全的治疗子宫肌瘤的药物。Objective：To observe the hs-CRP concentration after Mifepristone in the treatment of hysteromyoma and discuss the effect of Mifepristone in the treatment of hysteromyoma. Methods：We detected 100 cases of hysteromyoma patients＇ hs-CRP concentration by Nephelometry after Mifepristone treatment and compared with before treatment. Results：The hysteromyoma patients＇ hs-CRP level was higher than normal,the difference of patients＇ hs-CRP levels was statistically significant before and after Mifepristone in the treatment of hysteromyoma（P〈0.01） . Conclusion：Hysteromyoma patients＇ hs-CRP concentration after Mifepristone treatment is significantly reduce,hs-CRP as one of the effective index of Mifepristone in the treatment of uterine fibroids,Mifepristone is an effective and safe drug for hysteromyoma.

关 键 词：米非司酮 HS-CRP 子宫肌瘤 

分 类 号：R737.33[医药卫生—肿瘤]